The effect of imatinib mesylate therapy on angiogenesis and myelofibrosis was investigated and compared with interferon (IFN) and hydroxyurea (HU) in 98 patients with newly diagnosed Ph + /BCR-ABL + chronic myeloid leukemia in first chronic phase and no other pretreatment. By applying immunostaining (CD34) and morphometry a relationship between microvessel frequency and fiber density was detectable in initial bone marrow (BM) biopsies and sequential examinations after at least 8 months of therapy. First-line monotherapy with imatinib induced a significant reduction (normalization in comparison to controls) of microvessels and reticulin fibers. In most patients decrease in BM vascularity was associated with a complete cytogenetic response. A significant angiogenic effect was also observed after HU treatment, contrasting IFN administration or combination regimens (IFN+HU). In conclusion, our data support the angiogenic capacity of imatinib by normalization of vascularity. In contrast, hematological response following IFN treatment is independent from BM angiogenesis.
Introduction
Contrasting the wealth of data concerning efficacy of the tyrosine kinase inhibitor imatinib mesylate (STI571) in chronic myeloid leukemia (CML) [1] [2] [3] [4] [5] [6] scant knowledge exists about bone marrow (BM) findings. Preliminary results suggest a normalization of erythropoiesis accompanied by a marked reduction of granulocytes and megakaryocytes and a striking regression of fiber content. 7, 8 Concern has been expressed that cytoreductive pretreatment in the majority of these patients may have caused significant BM changes 9 and therefore may obscure the specific imatinib-related effects.
Persuasive evidence was provided that the microvascular endothelium within the hematopoietic microenvironment plays a pivotal role as gatekeeper controlling trafficking, differentiation, and homing of stem cells. 10 Because imatinib selectively inhibits growth of primitive malignant progenitors, 11 reports about increased vascularity in CML 12, 13 are of particular interest. Recent studies showed that levels of vascular endothelial growth factor (VEGF) expression were reduced in vitro by treatment with imatinib. 14, 15 In this context, preliminary data on BM biopsies confirmed the drug-related vascular effects. 16 However, in this study the frequency of microvessels was determined by crude quantification without focus on architectural features of angiogenesis or long term changes of therapy. For this purpose, we examined the effect of imatinib induced on BM microvasculature and fiber content in patients without any pretreatment in comparison with other therapeutic regimens. From the cohort of patients with first-line imatinib therapy 10 (71%) had a complete cytogenetic response, contrasting only 6 patients from the IFN group (18%) and 3 patients (16%) treated with IFN+HU. Finally, a control group of 25 patients without BM pathology was evaluated.
Study design

Morphometry and evaluation
Representative BM trephine biopsies were fixed in formalin, decalcified and paraffin wax embedded. According with other investigators 17 immunohistochemistry with CD34 + was applied as the endothelial antigen of choice for a proper identification of microvessels.
Staining reaction is very reliable with CD34, although few and dispersed progenitor cells are costained which are easily distinguishable from endothelial cells. 18 A blinded doublecrosschecked morphometric analysis was performed on biopsies with an artefact-free mean area of 15.4 ± 4.6 mm 2 by three independent investigators and further checked for accuracy by two others. Evaluation of the microvasculature regarded not only incidence of vessels in a certain section area, but also parameters reflecting more properly functional aspects of blood flow like luminal width and especially tortuosity and branching (shape factor, aspect ratio, maximal length, form factor). Following Gomori=s silver impregnation density of fibers was determined by the line-intersection count method using an ocular grid. According to this technique amount of fibers was expressed as intersections (i). 19 Quantification of these parameters was carried out at 500 x magnification by randomly selecting 50 fields of 3.77 x 10 -2 mm 2 in each specimen (total of 1.884 mm 2 BM area per biopsy). Reference to cellularity (hematopoietic area) was necessary to avoid the erroneous impression of a reduction in the quantity of corresponding vascular structures and fibers following a therapy-related expansion of adipose tissue or interstitial edema. The difference of each patients= preand posttreatment values was calculated with regard to vascular parameters as well as fiber density. Furthermore, the relative incidence of individual changes was evaluated for each treatment group.
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Results and discussion
The mean pretreatment value of 126 ± 50 for microvessel density (MVD) in the 98 patients with CML at diagnosis (Fig. 1a) contrasted significantly the normal control group (76 ± 26). According to the strictly defined treatment modalities imatinib and HU exerted a relevant impact on BM vascularity by showing a reduction in the number of vessels (Fig. 1b,c) . This conspicuous feature was easily demonstrable by morphometry. On the other hand, IFN or a combination treatment with HU (IFN+HU) failed to normalize the MVD. Changes in luminal width included a wide range of microvessel area (MVA) in the HU group and after treatment with imatinib. These findings were also associated with an increased vascular roundness and decreased tortuosity of microvessels (Fig. 1c) .
Corresponding with the enhanced MVD the pretreatment biopsies in all patients showed a mean fiber density of 41.0 ± 25.2 opposed to a lower value of the controls (16.5 ± 5.3).
Decrease in MVD during imatinib and HU therapy was associated with a reversal of myelofibrosis (Fig. 1d,e) , contrasting relevant findings after IFN or combination regimens. After 3 months of treatment with imatinib in all patients hematological remission was observed, compared to response rates of 76% and 54% within 6 months for the IFN and HU group. In most imatinib-treated patients (90%) occurrence of cytogenetic response was correlated with a significant reduction of BM vascularity. Accordingly, patients with complete molecular response revealed a normalization of the MVD. However, in the groups with IFN administration alone or in combination with HU, due to the small number of cytogenetic responses no significant correlation with the MVD was observed.
Extending previous studies on angiogenesis the MVD is not only significantly increased in CML, 12, 13 but also related to myelofibrosis. These changes following imatinib, but not IFN therapy have to be discussed by considering the complex interactions of various mediators involved in the remodeling and vascularity of the BM stroma. 20 In conclusion, the normalization of BM vascularity detectable during first-line treatment with imatinib is in most patients associated with complete cytogenetic response contrasting IFN therapy.
For Absolute changes during therapy (mean ± SD) For personal use only. on October 31, 2017. by guest www.bloodjournal.org From
